Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN null / Valor 1720684

NASDAQ (2025-10-21)
USD 146.22-0.28%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-20.8%1Y
-45.4%3Y
-45.6%5Y

Performance

30.3%1Y
33.0%3Y
41.7%5Y

Volatility

Market cap

21438 M

Market cap (USD)

Daily traded volume (Shares)

895,048

Daily traded volume (Shares)

1 day high/low

151.14 / 148.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

Demant A/S
Demant A/S Demant A/S Valor: 32651962
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.42%DKK 240.80
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc Syndax Pharmaceuticals Inc Valor: 24112479
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.38%USD 15.20
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.98%CHF 88.54
Sonova Holding Ltd.
Sonova Holding Ltd. Sonova Holding Ltd. Valor: 1254978
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.70%CHF 227.10
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.14%CHF 311.00
PolyPeptide Group Ltd
PolyPeptide Group Ltd PolyPeptide Group Ltd Valor: 111076085
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.69%CHF 24.05
Medartis Holding AG
Medartis Holding AG Medartis Holding AG Valor: 38620023
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.75%CHF 81.50
medmix Ltd
medmix Ltd medmix Ltd Valor: 112967710
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.33%CHF 9.25
Basilea Pharmaceutica Ltd, Allschwil
Basilea Pharmaceutica Ltd, Allschwil Basilea Pharmaceutica Ltd, Allschwil Valor: 1143244
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.10%CHF 48.65
Xlife Sciences Ltd.
Xlife Sciences Ltd. Xlife Sciences Ltd. Valor: 46192960
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.92%CHF 20.40